Skip to main content
Guerbet logo

Guerbet — Investor Relations & Filings

Ticker · GBT ISIN · FR0000032526 LEI · 969500WV1U1WQ059L135 PA Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2022-09-21 Regulatory Filings
Country FR France
Listing PA GBT

About Guerbet

https://www.guerbet.com

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Recent filings

Filing Released Lang Actions
Guerbet annonce l'approbation par la FDA du produit de contraste Elucirem™ (Gadopiclénol)
Regulatory Filings Classification · 95% confidence The document is a press release from Guerbet announcing the FDA approval of their contrast product EluciremTM (Gadopiclenol). It details the significance of the approval (priority review, reduced gadolinium dose), summarizes Phase III clinical trial results, and provides company background. This type of announcement, detailing a significant regulatory milestone (FDA approval) and providing key performance/safety data, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific financial filing, and it serves as the initial public announcement of a major event, 'Earnings Release' (ER) is the closest fit among the options for a major corporate/product news announcement, although 'Regulatory Filings' (RNS) could also apply if it were purely a regulatory filing notification. Given the structure as a formal press release detailing a major business event (FDA approval), ER is often used for such significant news releases, even if not strictly tied to quarterly earnings. However, since the core event is a regulatory approval announcement, and it is not a standard earnings report, 'Regulatory Filings' (RNS) serves as a strong general category for significant, non-standard corporate news releases. Given the context of a major product approval announcement, which is often disseminated broadly like an ER, but is fundamentally a regulatory event, I will lean towards RNS as the most appropriate catch-all for significant, non-standard corporate news that isn't a formal financial report or management change.
2022-09-21 French
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
Regulatory Filings Classification · 95% confidence The document is a press release announcing a significant corporate event: the U.S. Food and Drug Administration (FDA) approval of a new product, Elucirem™ (Gadopiclenol). This type of announcement, detailing regulatory milestones, clinical trial results supporting the approval, and future commercial plans, is characteristic of a general corporate news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a press release announcing a major business development (product approval), and it doesn't fit the specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV), the most appropriate general category for a significant, non-standard corporate announcement that is not a formal report is Regulatory Filings (RNS), which serves as a broad category for important public disclosures that aren't covered elsewhere, or potentially an Investor Presentation (IP) if it were structured as a deck, but this reads like a news announcement. Given the context of major regulatory news, RNS is the best fit as a general regulatory announcement/press release fallback.
2022-09-21 English
GUERBET: Résultats semestriels 2022
Earnings Release Classification · 100% confidence The document is titled "Résultats semestriels 2022" (Half-year results 2022) and explicitly announces "les résultats consolidés du premier semestre 2022" (the consolidated results for the first half of 2022). It contains detailed financial tables comparing H1 2021 and H1 2022 results (Revenue, EBITDA, Net Income) and discusses business segment performance for the first half of the year. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. Therefore, it should be classified as an Interim / Quarterly Report (IR). It is a full report, not just an announcement of a report (RPA). H1 2022
2022-09-21 French
Guerbet: 2022 half-year results
Earnings Release Classification · 95% confidence The document is a press release titled '2022 half-year results' for Guerbet. It provides a comprehensive summary of the company's financial performance for the first half of 2022, including revenue, EBITDA, operating income, net income, and net debt, along with management's analysis of business trends, geographic performance, and future outlook. While it contains financial data, it is structured as a corporate press release rather than a formal, audited interim financial report. According to the filing definitions, this fits the 'Earnings Release' (ER) category as it is the initial announcement of periodical financial results. H2 2022
2022-09-21 English
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE" (Declaration relative to the number of voting rights and shares comprising the capital of the company). It explicitly references French regulations (Code de commerce, AMF general regulation) and provides a table detailing the total number of shares, treasury shares, and total/exercisable voting rights as of August 31, 2022. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or capital structure disclosures related to voting rights.
2022-09-21 French
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE" (Declaration relative to the number of voting rights and shares comprising the capital of the company). It explicitly references French regulations (Code de commerce and AMF general regulation) requiring monthly publication of the total number of voting rights and shares. The content is a table showing the share count and voting rights as of July 31, 2022. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or, in this context, mandatory periodic disclosures related to voting rights structure.
2022-08-29 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.